Each monthly installment examines an aspect of multiple myeloma care, including delivering the diagnosis, building trust, ...

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

Patients with multiple myeloma (MM) have a distinct pattern of second primary malignancy (SPM), with a markedly increased ...

CAR T-cell therapy is a treatment that uses a patient’s own T cells, genetically reprograms them in a lab to recognize ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92% achieving MRD negativity. Safety profile is favorable, with no severe ...

CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina ...

Pfizer’s Phase 3 MagnetisMM-5 trial found that Elrexfio (elranatamab) significantly improved progression-free survival over a ...

We are entering an era where "cure," specifically a functional cure, is no longer a forbidden word in the myeloma community.

A healthcare provider shares her journey with multiple myeloma, discussing the physical, emotional and financial challenges ...

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained ...

How Does Multiple Myeloma Impact the Kidneys? Multiple myeloma is a cancer of plasma cells, a type of immune cell found in bone marrow. Healthy plasma cells make proteins called antibodies to fight ...

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...